Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy

Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a... case reports Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy 1 2 3 4 4 Maria I. Stamou, MD, PhD ; Christopher Chen, MD ; Seth A. Wander, MD ; Jeffrey G. Supko, PhD ; Dejan Juric, MD ; 3 5,6 Aditya Bardia, MD ; and Deborah J. Wexler MD MSc JCO Precis Oncol 6:e2100428. © 2022 by American Society of Clinical Oncology Introduction (coefficient of variation [CV], 2%). By comparison, the geometric mean steady state trough plasma concen- The serine/threonine–phosphoinositide 3-kinase pro- tration of ipatasertib in four other patients enrolled in tein B mammalian target rapamycin (PI3K-PKB/AKT/ the same arm of the study was 44.2 ng/mL (CV, 57%). mTOR-PAM) pathway regulates the cell proliferation. Given that she had not received any drug for 9 days, PAM kinases are overexpressed in malignancies, her residual plasma concentration of ipatasertib on prompting the development of PAM inhibitors (PAMi) C1D15 (16.7 ng/mL) was much higher than expected. as targeted cancer therapy. Apart from its important As calculated using the previously reported value of role in cell survival, the PI3K-AKT pathway’s role in 45.8 hours for the geometric mean apparent half-life of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JCO: Precision Oncology Wolters Kluwer Health

Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy

Loading next page...
 
/lp/wolters-kluwer-health/severe-lactic-acidosis-complicated-by-insulin-resistant-hyperosmolar-Mc0MFUzARv

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
© 2022 by American Society of Clinical Oncology
eISSN
2473-4284
DOI
10.1200/po.21.00428
Publisher site
See Article on Publisher Site

Abstract

case reports Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy 1 2 3 4 4 Maria I. Stamou, MD, PhD ; Christopher Chen, MD ; Seth A. Wander, MD ; Jeffrey G. Supko, PhD ; Dejan Juric, MD ; 3 5,6 Aditya Bardia, MD ; and Deborah J. Wexler MD MSc JCO Precis Oncol 6:e2100428. © 2022 by American Society of Clinical Oncology Introduction (coefficient of variation [CV], 2%). By comparison, the geometric mean steady state trough plasma concen- The serine/threonine–phosphoinositide 3-kinase pro- tration of ipatasertib in four other patients enrolled in tein B mammalian target rapamycin (PI3K-PKB/AKT/ the same arm of the study was 44.2 ng/mL (CV, 57%). mTOR-PAM) pathway regulates the cell proliferation. Given that she had not received any drug for 9 days, PAM kinases are overexpressed in malignancies, her residual plasma concentration of ipatasertib on prompting the development of PAM inhibitors (PAMi) C1D15 (16.7 ng/mL) was much higher than expected. as targeted cancer therapy. Apart from its important As calculated using the previously reported value of role in cell survival, the PI3K-AKT pathway’s role in 45.8 hours for the geometric mean apparent half-life of

Journal

JCO: Precision OncologyWolters Kluwer Health

Published: Jun 14, 2022

References